ERS 2026: oral IRAK4 inhibitor AZD6793 enters dose-ranging Phase IIb COPD trial

Phase 2AZD6793Neutral

AI Analysis

Summary

AstraZeneca presented Phase IIb trial design for oral IRAK4 inhibitor AZD6793 in COPD at ERS 2026. The PRESTO trial is a dose-ranging study investigating the compound's efficacy in this indication.

Clinical Trial Data

Phase

IIb

Importance:5/10

Sentiment:

0.20

IRAK4_inhibitorCOPDdose-rangingPRESTO_trialERS_2026

Related Companies

$AZN

Read the original article

Published by Clinical Trials Arena on September 11, 2026 1:15 PM

Read Original